Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma
Advanced Science · 2024
DOI: 10.1002/advs.202401789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Ying Zheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, C…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm, Mitochondria. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Outstanding Youth Fund Project, National Key Research and Development Program of China.
Abstract (Originalsprache)
Acquired resistance represents a critical clinical challenge to molecular targeted therapies such as tyrosine kinase inhibitors (TKIs) treatment in hepatocellular carcinoma (HCC). Therefore, it is urgent to explore new mechanisms and therapeutics that can overcome or delay resistance. Here, a US Food and Drug Administration (FDA)‐approved pleuromutilin antibiotic is identified that overcomes sorafenib resistance in HCC cell lines, cell line‐derived xenograft (CDX) and hydrodynamic injection mouse models. It is demonstrated that lefamulin targets interleukin enhancer‐binding factor 3 (ILF3) to increase the sorafenib susceptibility of HCC via impairing mitochondrial function. Mechanistically, lefamulin directly binds to the Alanine‐99 site of ILF3 protein and interferes with acetyltransferase general control non‐depressible 5 (GCN5) and CREB binding protein (CBP) mediated acetylation of Lysine‐100 site, which disrupts the ILF3‐mediated transcription of mitochondrial ribosomal protein L12 (MRPL12) and subsequent mitochondrial biogenesis. Clinical data further confirm that high ILF3 or MRPL12 expression is associated with poor survival and targeted therapy efficacy in HCC. Conclusively, this findings suggest that ILF3 is a potential therapeutic target for overcoming resistance to TKIs, and lefamulin may be a novel combination therapy strategy for HCC treatment with sorafenib and regorafenib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
ORCID-Profile: Hao Zhang
Förderung
- National Natural Science Foundation of China
- Jiangsu Outstanding Youth Fund Project
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- 111 project
- Higher Education Discipline Innovation Project
Zitieren
APA
Zheng, Y., Ye, S., Huang, S., Cheng, Y., Zhang, Y., Leng, Y., He, M., Wu, E., Chen, J., Kong, L., & Zhang, H. (2024). Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202401789
Vancouver
Zheng Y, Ye S, Huang S, Cheng Y, Zhang Y, Leng Y, et al. Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma. Advanced Science. 2024. doi:10.1002/advs.202401789
BibTeX
@article{Zheng2024,
author = {Zheng, Ying and Ye, Shengtao and Huang, Shiyu and Cheng, Yang and Zhang, Yanqiu and Leng, Yingrong and He, Mengmeng and Wu, Enyi and Chen, Junxin and Kong, Lingyi and Zhang, Hao},
title = {Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202401789}
}
EUVIMED